RxDoctor Payments DataLook up a doctor →

Alexandria Viscosi, APRN

Family · Wallingford, CTNPI 1881338275

Payments from drug & device makers

$11,713in general payments, 2019–2025

Across 585 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$973
  • Johnson & Johnson$792
  • Lilly USA, LLC$691
  • Axsome Therapeutics, Inc.$669
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$11,713100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,713 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$6,146
Medicare patients
14
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide33$39,590
SpravatoEsketamine Hcl29$34,748
SuboxoneBuprenorphine Hcl/Naloxone Hcl27$19,992
FarxigaDapagliflozin Propanediol19$9,596
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl47$6,643
VascepaIcosapent Ethyl15$5,621
Diclofenac Sodium12$726
Buprenorphine Hcl16$704
Omeprazole27$619
Rosuvastatin Calcium15$581
Ibuprofen14$352
Levothyroxine Sodium16$315
Mirtazapine11$306
Pregabalin12$303
Atorvastatin Calcium54$274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$691$39,59033 claims
Johnson & JohnsonSpravato$792$34,74829 claims
Indivior Inc.Suboxone$598$19,99227 claims
AstraZenecaFarxiga$1,069$9,59619 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl$53$7,34663 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.

Other family in Wallingford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →